Navigation Links
IDRI Announces Appointment of Dr. Karen Auditore-Hargreaves as SVP, Scientific Affairs
Date:3/5/2009

Two new Directors join the Board of the growing global health organization

SEATTLE, March 5 /PRNewswire-USNewswire/ -- IDRI (Infectious Disease Research Institute) announced today that Dr. Karen Auditore-Hargreaves has joined IDRI as Senior Vice President (SVP) Scientific Affairs to assist the organization in the execution of its research and development programs. Dr. Auditore-Hargreaves has a proven track record in scientific management and has held senior leadership positions with leading biotech companies.

"I am delighted to welcome Karen Auditore-Hargreaves as a new member of IDRI's management team," said Curt Malloy, SVP Operations and General Counsel at IDRI. "Her appointment and her broad biotech experience signify our commitment to building a strong organization that delivers on its scientific objectives."

Karen Auditore-Hargreaves joins IDRI after 3 years as Chief Executive Officer and President of cancer vaccine company ODC Therapy, in Dallas, Texas. Prior to that, she served for 6 years as President and Chief Operating Officer of NeoRx Corporation, in Seattle, Washington, (an organization currently doing business as Poniard Pharmaceuticals). Poniard is a publicly traded biotech company developing small-molecule drugs and targeted biologics for cancer.

"Her background in drug development, along with her deep understanding of the immune system, are an exciting fit with IDRI's three-pronged mission to prevent, detect and treat infectious diseases of poverty," added Curt Malloy.

Before joining NeoRx Corporation, Dr. Hargreaves held senior research management positions with CellPro, Oculon Corporation, PATH and Genetic Systems Corporation. Dr. Hargreaves holds a PhD in Genetics from the University of California, Davis, and received her post doctoral training at the Massachusetts Institute of Technology Center for Cancer Research.

Dr. Steven Reed, IDRI's founder and Head of Research and Development commented, "Dr. Auditore-Hargreaves possesses a unique combination of leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them. She is a great addition to IDRI's team."

IDRI also announced today that Dr. Christopher D. Earl, President and CEO of BIO Ventures for Global Health (BVGH), and David P. Perry, President and Chief Executive Officer of Anacor Pharmaceuticals, Inc., have been appointed to IDRI's Board of Directors. The addition of Earl and Perry to the Board increase the total membership to ten.

"In order to further strengthen IDRI as a growing organization, the Board has been working diligently to identify directors with excellent knowledge of life sciences," said Steve Davis, Chairman of IDRI's Board. "Chris and David bring a wealth of biotech leadership experience, and their passion and strong sense of commitment will be great assets to IDRI. We look forward to working with them to help IDRI achieve its mission against diseases of poverty."

Dr. Christopher D. Earl is President and CEO of BIO Ventures for Global Health (BVGH), a not-for-profit organization whose mission is to harness the resources of the biotechnology industry to create new medicines for infectious diseases of the developing world. BVGH breaks down barriers that hinder industry initiatives in global health product development. The organization fosters collaboration among stakeholders in industry, philanthropy, academia, and government, and catalyzes industry investment through the creation of new market-based incentives. Dr. Earl previously served as Managing Director of the Perseus-Soros BioPharmaceutical Fund, LP, a leading investor in later-stage life science companies, where he managed investments in biopharmaceutical companies and served as a director on portfolio company boards. Dr. Earl received a BA in Biology from the University of Pennsylvania, and a PhD in Cellular and Developmental Biology from Harvard University. For further information on BIO Ventures for Global Health, please visit www.bvgh.org.

David Perry has served as Anacor Pharmaceuticals' President and Chief Executive Officer since March 2002 and has been a member of its board of directors since April 2002. Anacor Pharmaceuticals is a biopharmaceutical company developing novel small-molecule therapeutics derived from its boron chemistry platform to treat infectious and inflammatory diseases. In 1997, Mr. Perry founded Chemdex Corporation, which was acquired by NexPrise, Inc., a business-to-business marketplace company that focused on the life-sciences industry and, until November 2001, served as its Chief Executive Officer. In 1995, Mr. Perry co-founded Virogen, a biotech company based in Boston. Mr. Perry has a BS from the University of Tulsa and an MBA from Harvard Business School. For further information on Anacor Pharmaceuticals, Inc., please visit www.anacor.com.

IDRI - Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect and treat infectious diseases of poverty. By integrating capabilities, IDRI strives to create an efficient pathway to bring scientific innovation from the lab to the people who need it most. For more information, go to www.idri.org.


'/>"/>
SOURCE Infectious Disease Research Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Announces Appointment of Chief Financial Officer
2. HMS Holdings Corp. Announces Executive Promotions
3. Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center
4. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
5. Medifast, Inc. Announces Appointment of Two Additional Independent Board Members
6. CorMatrix Cardiovascular Announces First European Implants of CorMatrix(R) ECM Technology(TM)
7. SXC Health solutions announces strong fourth quarter and year end financial results
8. Stemedica Announces the Appointment of Carl Bullen as Director of Manufacturing
9. PharmaNet Development Group Announces Flexible Staffing Business
10. Weight Watchers Announces Fourth Quarter and Full Year 2008 Results
11. Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Wausau, WI (PRWEB) , ... February 27, 2017 , ... ... Young Investigator Award. Dr. Chen will receive his award during the Plenary Session at ... Inc. (ASLMS), to be held in San Diego, California April 5-9, 2017. , ...
(Date:2/27/2017)... ... 27, 2017 , ... Robert E. Burke, MD, PhD, had a successful career ... and life experiences could have led him down a much different path. , In ... Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of the tribulations he ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare ... for a company involved in the underground testing of nuclear weapons. Years later, when ... Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made ...
(Date:2/27/2017)... ... 27, 2017 , ... This webinar , sponsored by ... tool to characterize particle size distributions in the field of geoscience and soil ... scientific findings. It describes methods of optimized and standardized sample collection, preparation and ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... mark last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... March 2014. The company had 800 customers and 2,250 RCEs at the time ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... The global  pulse oximeters market  is expected to reach USD 2.8 ... The pulse oximeters market is anticipated to witness significant growth during the forecast ... as chronic obstructive pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic conditions. ... ... Grand View Research Logo ...
(Date:2/28/2017)... This report provides all the information you require to ... since 2010. Download the full report: ... Alliance since 2010 report provides an in-depth insight into ... life sciences companies. On demand company reports ... most up to date deal and company data. ...
(Date:2/28/2017)... , Feb 28, 2017 ... Research and Markets ... 2025" report to their offering. The global ... The orthobiologics market is predominantly driven by ... technological innovations in biomaterials, used in the production of orthobiologics are ...
Breaking Medicine Technology: